QualityStocks'  Instablog

Echo Therapeutics yesterday announced positive results from its clinical trial of the Symphony tCGM System, a needle-free, noninvasive, wireless, transdermal continuous glucose monitoring system. This study, conducted in 15 elective cardiac surgery patients, has been the first of two studies the company is conducting in critically ill patients; results from the second study are expected later this quarter.

As evidenced in data from the study, Symphony successfully and continuously monitored glucose levels in Boston's Tufts Medical Center cardiothoracic surgical intensive care unit. Data analysis also demonstrated that Symphony was accurate in reading glucose levels, with a mean absolute relative difference, or error rate, of 12.3%. The study conducted by Echo has produced clinical evidence indicating that this continuous technology can be safely used in critically ill patients for sustaining glucose levels within a target range. The system's ease of use and potential cost savings additionally show that Symphony could transition with critically ill patients from the ICU to a hospital's general floor, where better technologically assisted glucose control is vitally needed. For further details about the study, visit echotx.com.

Echo Therapeutics is a transdermal medical device company with profound expertise in advanced skin permeation technology. The company is currently engaged in developing its Symphony tCGM System and its needle-free Prelude SkinPrep system, which is a platform technology enabling significantly enhanced, painless skin permeation for delivering needle-free drugs and enabling analyte extraction. Echo Therapeutics believes that transdermal drug delivery and analyte monitoring form a superior system of patient care, in contrast with the current paradigm of invasive needle-based therapy.

For more information, visit the company's website at echotx.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net